Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Aug 19;333(7564):380-4.
doi: 10.1136/bmj.333.7564.380.

Psoriasis and its management

Catherine H Smith  1 , J N W N Barker
Affiliations
Review

Psoriasis and its management

Catherine H Smith et al. BMJ. .
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Plaques show varying degrees of scaling, thickening (induration), and inflammation (redness) are typically oval shaped, of variable size (from less than 1 cm upwards), and clearly distinct from adjacent normal skin. Characteristic nail changes include pitting (shown), onycholysis, and subungual hyperkeratosis
Fig 2
Fig 2
Histologically, psoriasis is characterised by epidermal thickening (arrow a) as a result of proliferation and impaired maturation of keratinocytes (normal cycle of keratinocyte maturation is 28-30 days whereas in psoriatic plaques this accelerates to three or four days), leucocyte infiltration (arrow b), and new blood vessel formation (angiogenesis)
See this image and copyright information in PMC

References

    1. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nature 2005;5: 699-711. - PubMed
    1. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113: 1664-75. - PMC - PubMed
    1. Boyman O, Hefti HB, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004;199: 731-6. - PMC - PubMed
    1. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366: 1333-5. - PubMed
    1. Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2000;143: 979-82. - PubMed

Substances